Articles tagged with Cancer Stem Cells
Researchers found that toddlers with profound autism had larger embryonic brain cortical organoids (BCOs) compared to neurotypical controls. The BCO size was positively correlated with the child's later social symptoms, indicating that a larger brain may be the first sign of autism.
Researchers have developed a model to enrich sub-populations of cancer cells with high basal levels of mitophagy, promoting CSC features such as self-renewal, proliferation, and drug-resistance. This study highlights the importance of BNIP3/BNIP3L in maintaining cancer stem cell properties.
Researchers at UCLA have identified a key protein MYCT1 that enables blood stem cells to sense and interpret signals from their environment. The study's findings could lead to the development of methods to expand blood stem cells in a lab dish, making life-saving transplants more available.
Researchers at Texas A&M University have discovered a new technique for tissue regeneration using mineral-based nanomaterials inspired by ancient medical practices. The approach aims to induce natural bone formation, reducing the need for invasive procedures and long-term medication, and promoting improved quality of life.
Research led by Weill Cornell Medicine found that most colorectal cancers begin with the loss of intestinal stem cells, even before cancer-causing genetic alterations appear. This new understanding suggests a unified model for colorectal cancer initiation where damage to intestinal crypts causes a decrease in aPKC protein expression.
Researchers explore nanoparticle-based therapies to specifically target lymphatic metastasis in breast cancer, providing a promising solution for patient treatment. Nanoparticles deliver drugs directly to tumors, targeting cancer cells to destroy them or slow their growth, while also enhancing the immune response.
Researchers at Sylvester Comprehensive Cancer Center have developed a new treatment approach that enables more patients with high-risk blood cancers to receive stem cell transplants from unrelated, partially matched donors. The study found an overall survival rate of 79% and impressive metrics in high-risk patients.
Scientists have discovered 17 new genes involved in clonal haematopoiesis, a process associated with ageing linked to increased risks of blood cancers. The findings highlight the clinical significance of these genes in driving mutant blood cell clones, offering new avenues for studying disease development and promoting healthier ageing.
Researchers have uncovered a novel regulator governing how cells respond to mechanical cues, finding that ETV4 bridges cell density dynamics to stem cell differentiation. This discovery has significant implications for controlling cancer cells through mechanical cues.
Researchers found that ~60% of tissues exhibit a significant negative correlation between age and stemness score, indicating a pan-tissue decline in stemness. This study adds weight to the idea that stem cell deterioration contributes to human aging, with hematopoietic stem cells from older individuals showing higher stemness scores.
Researchers discovered MIA-602's effectiveness against Doxorubicin-resistant acute myeloid leukemia (AML), demonstrating reduced cell viability and tumor volume. The study suggests MIA-602 as a potential alternative treatment approach for AML, potentially circumventing chemotherapy side effects.
Researchers highlight the role of post-transcriptional RNA modifications in AML pathogenesis, identifying m6A and m7G regulators as potential therapeutic targets. Targeted therapies, including selective inhibitors and Traditional Chinese Medicine compounds, show promise in promoting cell differentiation and reversing AML phenotypes.
Scientists at Cincinnati Children's Hospital Medical Center have created the most detailed atlas of human blood stem cells, identifying over 80 distinct subsets. The study provides new insights into the development of leukemia and potential biomarkers for clinical monitoring.
A new study reveals distinct transcriptional programs and molecular features in right-sided colon stem cells, which may help explain the differences in colon cancer development. The research also highlights the importance of CDX2 in regulating stem cell differentiation and tumor initiation.
Researchers discovered that the vitamin D/vitamin D receptor pathway protects enterocytes during aging, reducing ISC proliferation and centrosome amplification. This study provides insights into the molecular mechanisms underlying healthy aging in Drosophila.
Researchers discovered genes encoding growth regulators normally not present in myeloid cells are expressed by leukaemic stem cells, allowing them to grow. Repurposed drugs targeting these receptors show promise in blocking stem cell growth and preventing disease relapse in specific types of AML.
A new study from the University of Ottawa proposes using vanoxerine, a drug initially developed for cocaine addiction, to potentially treat advanced colon cancer. Vanoxerine has been found to suppress cancer stem cell activity in colon cancer patients' tissues and tumours implanted in laboratory animals. The drug works by interfering w...
A team of scientists has developed a new type of anticancer agent targeting cancer stem cells, which are difficult to eradicate. The compound, called Ru1, promotes a decrease in the expression of genes necessary for mitochondrial respiration, causing cancerous cells to lose their potential.
A recent study reveals that a significant proportion of human pluripotent stem cell samples possess cancer-related mutations acquired during culture propagation. These mutations impact cell growth and differentiation, emphasizing the importance of regular evaluations in research and clinical applications.
Researchers found that ASCOT reverses some age-related protein expression changes, enriching processes related to the complement cascade and immune system in patients with poor ovarian response. In contrast, patients with premature ovarian insufficiency showed enrichment in responses to oxygen-containing compounds and growth hormones.
Cancer stem cell-derived exosomes (CSC-Exos) are essential for communication between CSCs and other cells in the tumor microenvironment, contributing to cancer progression. The editorial highlights their potential as a novel clinical tool for diagnosis, prognosis, prevention of tumor recurrence, and therapeutic strategy
Researchers at Hokkaido University found that cancer stem cells cause macrophages to age, suppressing their antitumor activity. Supplementing mice with nicotinamide mononucleotide restored macrophage function and prevented tumor growth.
Scientists from Tokyo Medical and Dental University created a synthetic polymer biomaterial that mimics the pancreatic adenocarcinoma microenvironment, enabling them to identify potential therapeutic targets. The study successfully recapitulates the complex interactions between cancer stem cells and their niche.
Researchers found that apoptotic cells induce apoptosis in neighboring hair follicle cells during the regression cycle. The study proposes a mathematical model of the hair follicle regression cycle, which suggests that the dermal papilla plays an essential role in initiating apoptosis.
The NYSCF – Robertson Stem Cell Investigator Awards support promising early career scientists with cutting-edge research, providing $1.5 million over five years for seed funding. The latest cohort includes three talented researchers who will join the thirteenth class of NYSCF – Robertson Stem Cell Investigators.
Researchers discovered that inhibiting the BRAF/EGFR/MEK pathway significantly reduced cancer stemness and drug resistance in primary colorectal cancer cells. The study also identified a triple combination treatment against BRAF, EGFR, and MEK as a promising approach to block these activities and develop effective treatments.
Researchers identified abnormal keratin expression patterns in senescent ocular surface cells, which may contribute to severe ocular surface diseases. Gene expression profiles showed substantial differences between senescent and non-senescent cells, highlighting their potential role in pathology.
A new biomimetic chip has been developed to simulate the human gastric mucosa, combining organoid and organ-on-a-chip technologies. The biochip replicates mechanical stimulation and cell-to-cell interactions, mimicking key features of the human stomach's defense mechanisms.
Researchers at Weill Cornell Medicine discovered a distinct type of stem cell that secretes protein MFGE8, favoring tumor metastases to the spine. This finding helps explain why solid tumors often spread to the spine and could lead to new orthopedic and cancer treatments.
Researchers developed a new formulation of doxorubicin that targets cancer cells while reducing cardiotoxicity. The protein-shell encapsulation increases specificity for cancer cells and decreases harm to healthy heart cells.
Researchers developed a new strategy to target CD45, a surface marker found on nearly all blood cells, using CRISPR base-editing. This approach aims to overcome challenges in CAR T cell therapy, which currently targets specific cancer types, and could expand treatment options for virtually all blood cancers.
A new study by Weill Cornell Medicine researchers found that severe COVID-19 infection can alter the immune system's response, causing long-lasting changes to gene expression in immune system stem cells. This can lead to symptoms of prolonged inflammation and 'long COVID' in affected individuals.
Scientists from the University of Copenhagen found that cancer cells have different ribosomes compared to other cells, which produce specific proteins. This discovery may lead to improved treatments in regenerative medicine and potentially better treatments for cancer.
A study published in Nature Cell Biology found that blood stem cell diversity arises during embryonic development and can be manipulated in childhood to improve overall health. The researchers used zebrafish and human pluripotent stem cells to demonstrate the potential of enhancing blood stem cell production.
A novel association of t(5;17) with t(8;21) has been reported in an acute myeloid leukemia (AML) patient, resulting in a RUNX1-RUNX1T1 rearrangement. The patient received chemotherapy and stem cell transplantation, highlighting the importance of this rare translocation.
A collaborative study by researchers at the University of Ottawa and McMaster University has made a groundbreaking discovery linking different types of cancers to their embryonic origins. The team found that drugs targeting specific embryonic pathways can effectively treat various tumors, including brain, colon, and leukemia cancers.
Cancer cells can hide and escape therapies leading to recurrence. Researchers identify three possible mechanisms: cancer stem cells, polyploidy, and senescence. Combination treatments involving chemoradiation-induced transitory senescence and senolytic therapies may be effective in preventing repopulation.
Patients with GATA2 deficiency have impaired ability to produce immune cells, leading to increased risk of recurrent infections and blood cancers. The study's findings suggest that a zebrafish model may help develop new treatments to slow or reverse the disease.
Scientists from Brigham and Women's Hospital have developed a new immuno-therapeutic approach using twin stem cells that can target brain metastatic melanomas. The therapy, which uses an engineered 'twin stem cell model,' activates the immune system to suppress tumor growth and prolong survival in representative preclinical models.
Researchers discuss chemotherapeutic resistance in recurring ovarian cancer, focusing on the unfolded protein response and its effect on polyploid giant cancer cells. Understanding this mechanism could lead to investigating cancer cell molecular mechanisms and potential therapeutic strategies.
Increased expression of Musashi 1 on breast cancer cells has significant implications for understanding dormancy and survival in bone marrow. Msi 1 knockdown led to a reduction in cancer stem cells with undetectable PD-L1, suggesting a potential therapeutic target.
Scientists have developed a new method to deliver genetic information to stem cells using nanoparticles coated with a specific polymer, enabling more efficient control over cellular differentiation. This innovation has the potential to improve the efficiency and effectiveness of regenerative medicine treatments.
A multi-institutional phase 3 clinical trial found that a cancer stem cell test can accurately decide more effective treatments and lead to increased survival for patients with recurrent glioblastoma. ChemoID, a CLIA-accredited diagnostic test, was used to select chemotherapy treatments, resulting in significantly lower risk of death a...
Researchers discovered that gamma delta T cells can effectively combat triple-negative breast cancer by targeting stress-induced molecules and phosphoantigens. Counteracting metabolic changes with zolendronate makes immunotherapy more efficient.
A new method, CloneTracer, distinguishes between cancerous and healthy stem cells in acute myeloid leukemia (AML). The study reveals two distinct stem cell compartments and shows that progenitor cells respond better to therapy. This finding paves the way for developing new techniques to predict patient response to chemotherapy.
Researchers at Trinity College Dublin have discovered a new process that explains why cells have unique identities. By studying Polycomb protein complexes, the team found that different forms of these proteins recruit distinct complexes to DNA, shedding light on cellular identity and its potential impact on cancer treatments.
A new fluorescent probe, TiY, has been developed to selectively target and kill cancer stem cells, which are responsible for tumor growth. The probe can be used to simultaneously diagnose and treat cancer, offering a promising approach to improving cancer treatment outcomes.
Researchers at Lund University discovered a novel mechanism linking RNA splicing to the development of leukemia in myelodysplastic syndrome patients. The study highlights the critical role of core spliceosome component SF3B1 and its regulation by N6-methyladenosine (m6A) modification, which provides a
Researchers have discovered a late-stage small molecule inhibitor called rebecsinib that reverses ADAR1-induced cancer stem cell cloning capacity. This breakthrough has significant implications for treating various types of cancers, including acute myeloid leukemia and chronic myeloid leukemia.
A novel form of chemoimmunotherapy has been proven to be a promising treatment for canine cancer, extending the lives of terminally ill dogs. The therapy uses modified Mesenchymal Stem Cells carrying a potent 'kill-switch' that induces anti-cancer immunity and improves quality of life.
Researchers at Children's Hospital of Philadelphia have developed a custom-built application to automate the determination of engraftment after hematopoietic stem cell transplant. The tool has been shown to improve accuracy of reported engraftments, reducing errors in neutrophil and platelet engraftment reporting.
Researchers found that activating the non-mutated form of P53 can change the fundamental makeup of cancer stem cells in mouse models of mucoepidermoid carcinoma. This new therapy approach shows promise for treating this lethal form of salivary gland cancer.
A study published in Nature reveals that cancer stem cells' miscommunication with their environment can trigger a self-perpetuating series of events leading to malignancy. Leptin signaling plays a surprising role in this process, which could be blocked to prevent tumor progression.
Researchers at the University of Waterloo have identified a new method for scheduling radiation therapy that could be up to 22% more effective at killing cancer cells. The algorithm takes into account the differing radiation resistances of stem cells and non-stem cells, allowing doctors to predict how a tumour will respond to treatment.
The New York Stem Cell Foundation (NYSCF) has selected six early-career researchers to join its prestigious investigator program, which provides $1.5 million in funding over five years. The award aims to accelerate treatments and cures through cutting-edge research.
WayPath Pharma has been awarded a $225,000 Phase I Small Business Technology Transfer (STTR) award to develop new metabolic drugs targeting tumor stem cells and crossing the blood-brain barrier. The funding aims to advance treatment options for glioblastoma, a highly aggressive brain cancer with limited treatment options.
Researchers have discovered a new pathway for producing telomerase RNA from protein-coding messenger RNA, offering potential innovations in mRNA vaccines and understanding of telomere biology. This finding has implications for reversing cellular aging and extending human lifespan.
Researchers have identified a small molecule drug, SHP656, that can target the circadian clock proteins responsible for glioblastoma's recurrence and spread. The drug has shown promise in reducing cancer stem cell growth without harming normal stem cells.
Researchers at UBC develop new process to produce T cells, the most essential human immune cells, in the lab with improved efficiency. The breakthrough could lead to cost-effective production of cancer-fighting cells for CAR T therapy, a treatment with an efficacy rate of close to 50%.
A study published in Cancer Research found that constitutively activated p53 in hepatocytes of chronic liver disease patients creates a microenvironment supportive of tumor formation from hepatic progenitor cells. This novel mechanism challenges the traditional role of p53 as a cancer suppressor.